Adipin

Quick links to important sections

Adipin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adipin

Property Description
Active ingredient Amlodipine
Form Oral Tablet
Pharmacological class Calcium Channel Blocker (CCB)
General purpose Management of high blood pressure and angina
Origin Synthetic Dihydropyridine

What Type of Medicine is Adipin?

Adipin is a synthetic, prescription-only cardiovascular medication containing the active substance Amlodipine. It is formally classified as a calcium channel blocker (CCB), primarily functioning as an antihypertensive and antianginal agent. Amlodipine is a Third-generation dihydropyridine, a specific subset of calcium antagonists that influences the body's vascular system. This classification is clinically recognized for providing effective, sustained control over systemic vascular resistance, and its prolonged action is beneficial for sustained blood pressure management. The primary therapeutic focus of this classification is to address conditions such as hypertension (high blood pressure) and chronic stable angina by supporting stable cardiovascular function in adult patients.

Composition, Form, and General Purpose

Adipin is supplied as an oral preparation in the physical form of a tablet, making it a convenient solid pharmaceutical delivery system. It is defined as a monotherapy preparation because it contains Amlodipine (typically utilized as the besilate salt) as its sole active ingredient. The general purpose of Amlodipine stems from its action as a calcium antagonist: it selectively blocks the cellular entry of calcium ions into the walls of the arteries. This inhibition of calcium influx prompts the vascular smooth muscle to relax, leading to significant peripheral vasodilation—the widening of arteries throughout the body. The resulting reduction in circulatory resistance is a physiologically established effect that effectively eases the strain on the heart, directly supporting improved cardiovascular function and decreasing the overall workload on the heart.

Regulatory References

  1. NIH MedlinePlus on Amlodipine
  2. NCBI Bookshelf on Amlodipine/Calcium Channel Blockers

What side effects are possible with Adipin?

Possible Side Effects and Safety Information

The safety profile for Adipin is well-documented, with adverse reactions generally categorized by their frequency in clinical data.

Adverse Reactions

The most frequently reported side effects are classified as common (occurring in 1% to 10% of patients), and primarily involve the nervous system, general disorders, and the gastrointestinal system.

System-Organ Class Common Adverse Reactions
General Disorders Fatigue, Edema (swelling, particularly of ankles/feet)
Nervous System Headache, Somnolence (sleepiness), Dizziness
Gastrointestinal Nausea, Abdominal pain
Vascular/Other Flushing, Palpitations

Serious and Clinically Significant Safety Concerns

Although rare, certain adverse effects require particular attention:

  • Hypotension: A significant drop in blood pressure can occur, especially at the start of treatment or following a dose increase. This may manifest as dizziness or fainting.
  • Worsening Angina/Myocardial Infarction: In rare instances, patients with severe underlying coronary artery disease may experience a worsening of chest pain or acute heart attack shortly after starting the medicine or increasing the dose.
  • Liver Function: Liver problems, including jaundice (yellowing of the skin or eyes) have been reported rarely. Monitoring of liver function is advised.

Safety Precautions in Specific Populations

  • Pregnancy: The drug may be unsafe for the developing fetus. Use during pregnancy requires a careful clinical assessment of the risk versus benefit.
  • Liver Impairment: Patients with liver disease should be treated with caution, typically starting at a lower dose and requiring close monitoring.
  • Older Adults: Older patients may be more susceptible to the effects of the medicine, and lower initial doses may be considered to mitigate risk.

Restrictions and General Safety Notes

Because Adipin can cause dizziness or fatigue, patients are advised to exercise caution when driving or operating machinery until they are familiar with how the medication affects them. Concomitant use with alcohol may increase the risk of dizziness and other side effects.

Overdose and Emergency Response

When overdosage of Adipin (Amlodipine) is suspected, immediate medical attention must be sought. Official regulatory documentation states that an overdose may result in excessive peripheral vasodilation, leading to severe clinical signs, particularly marked hypotension (a serious drop in blood pressure) and a resultant reflex tachycardia (accelerated heart rate).

In such a severe situation, active cardiac and respiratory monitoring is required, and frequent blood pressure measurements are designated as essential. Emergency management focuses entirely on cardiovascular support. This mandated procedural response includes supportive measures such as the elevation of the extremities and the judicious administration of intravenous fluids. If marked hypotension remains unresponsive to these conservative actions, official guidance describes the required use of vasopressors, such as phenylephrine.

The regulatory profile notes that no specific antidote is known for Amlodipine overdosage. Due to the substance being highly protein bound, official sources confirm that hemodialysis is not likely to be of benefit in the removal process. Because of the drug's long half-life, a period of hospital monitoring or an overnight stay may be required even after initial symptoms are controlled.

Therapeutic Uses of Adipin

What Adipin Treats: Main Uses and Benefits

Adipin is commonly used for the sustained management of chronic cardiovascular conditions. The medication is primarily used to help address elevated blood pressure, known as hypertension, in both adults and pediatric patients aged 6 to 17. It is commonly used to help with managing chronic stable angina and vasospastic angina. The therapeutic benefit generally helps sustain lower blood pressure levels, which contributes to reducing the risk of cardiovascular complications.

This supportive therapeutic benefit may assist with reducing the long-term risk of serious cardiovascular events and assists with maintaining functional stability over time.

“This preventative use provides support that helps reduce the frequency and severity of anginal episodes, allowing patients to better cope with symptom fluctuations.”

Additionally, Adipin is applied in contexts of coronary artery disease, where it may assist with reducing the risk of hospitalization for angina. This helps patients cope more steadily with symptom fluctuations and helps address the recurrent symptoms related to physical discomfort (tightness or pressure in the chest) that interfere with daily functioning.


Quick Fact: Supportive Management for Anginal Chest Discomfort and Systemic Imbalance (High Blood Pressure)

Regulatory References

  1. NIH MedlinePlus overview of Amlodipine

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Profile

Adipin use is strictly governed by regulatory documentation defining populations who are eligible, require caution, or are strictly excluded. This profile is not clinical advice and should be reviewed with a healthcare professional.

Contraindicated Populations (Must Not Use) Specific Eligibility Constraints
Known hypersensitivity to Amlodipine or other dihydropyridines. Patients with severe hepatic impairment require careful monitoring and possible dose reduction.
Severe hypotension (low blood pressure). Use in patients with congestive heart failure requires caution.
Cardiogenic shock or significant aortic stenosis. Older adults may require a lower initial dose.
Lactating/Nursing women (generally not recommended or contraindicated). Pregnancy use is generally not recommended unless necessary for severe maternal conditions.

Age-Related Eligibility: Adipin's safety and efficacy are established for hypertension in children aged 6 to 17 years. Use is not established and not recommended for children younger than six years old.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Adipin (Amlodipine)

Property Description
Medicinal product categories with documented interactions Strong and moderate CYP3A4 inhibitors, CYP3A4 inducers, other antihypertensive agents, HMG-CoA reductase inhibitors (statins), and certain immunosuppressants.
Specific interacting medicines (if explicitly listed) Dantrolene (intravenous), Clarithromycin, Ketoconazole, Ritonavir, Rifampicin, St. John's Wort (Hypericum perforatum), Simvastatin, Cyclosporine, Tacrolimus, and Sildenafil.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction (CYP3A4): Amlodipine is a substrate of CYP3A4; strong/moderate inhibitors increase amlodipine exposure. Amlodipine is also a weak CYP3A4 inhibitor, increasing exposure of certain co-administered drugs. Pharmacodynamic interaction: Additive blood pressure-lowering effect.
Timing-based interaction rules (if applicable) Co-administration of Grapefruit or Grapefruit Juice is not recommended as bioavailability may be increased in some patients, potentially enhancing its effects.
Population-specific interaction notes (if applicable) The clinical significance of CYP3A4 inhibitor interactions may be more pronounced in the elderly. Clearance is decreased in patients with severe hepatic impairment, which may lead to increased systemic exposure.
Interaction-related restrictions The daily dose of Simvastatin should not exceed 20 mg when co-administered with Amlodipine due to the documented increase in Simvastatin exposure (AUC).

Interaction Classifications (High-Level)

Property Description
Interaction severity classification (as defined in official documents) Avoid (e.g., Dantrolene IV, Grapefruit); Dose Restriction Mandated (e.g., Simvastatin); Monitoring Required (e.g., CYP3A4 Inhibitors, other Antihypertensives).
Regulatory basis (EMA / FDA / etc.) Based on official Summary of Product Characteristics (SmPC) and FDA Prescribing Information.
Interaction-context constraints (as defined in official documents) Dantrolene (IV) co-administration is advised to be avoided in patients susceptible to malignant hyperthermia. Tacrolimus and Cyclosporine co-administration requires monitoring of blood levels.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with strong or moderate CYP3A4 inhibitors results in a documented increase in systemic exposure of Amlodipine.
  • Amlodipine co-administration with other antihypertensive agents or Sildenafil may produce an additive antihypertensive effect.
  • The co-administration of Simvastatin resulted in a 77% increase in the statin's exposure (AUC), leading to the regulatory mandate that its daily dose must not exceed 20 mg.
  • The combination with intravenous Dantrolene is advised to be avoided due to the documented risk of hyperkalaemia in related models.
  • Amlodipine may increase the blood levels of the immunosuppressants Tacrolimus and Cyclosporine.

Connection to the overall interaction profile (2–4 sentences): Official regulatory documents define Amlodipine's interaction profile across pharmacokinetic and pharmacodynamic domains. The primary pharmacokinetic concerns involve its metabolic pathway (CYP3A4), where inhibition increases Amlodipine exposure. The pharmacodynamic classification centers on an additive effect when combined with other blood pressure-lowering agents, establishing the structural basis for monitoring and dose restrictions as mandated by regulatory authorities.

Mechanism of Action

How Adipin Works: Mechanism of Action

Calcium Channel Blockade and Molecular Action

Adipin exerts its primary action by functioning as an inhibitor of L-type voltage-dependent calcium channels (Cav1.2) found on the cell membranes of vascular smooth muscle. This specific molecular blockade prevents the influx of extracellular calcium ions (Ca^2+) into the cell, which is the initial step that influences the subsequent mechanistic sequence.


Regulation of Vascular Tone and Peripheral Resistance

By limiting the availability of intracellular calcium, Adipin interrupts the excitation-contraction coupling process, leading to the relaxation of arterial smooth muscle. This vasodilation directly reduces the systemic vascular resistance (SVR), decreasing the overall impedance to blood flow and altering the dynamics within the vascular tone regulation system.


️ Decreasing Myocardial Workload (Afterload)

The resulting decrease in SVR decreases the force, or afterload, generated by the left ventricle during ejection. This physiological adjustment reduces the myocardial oxygen demand and, alongside the drug’s action to dilate coronary arteries, influences the oxygen supply-to-demand relationship in the heart muscle.

Dosage and Administration Information

Adipin (Amlodipine) is administered orally once per day for the chronic management of cardiovascular conditions. The tablets may be taken with or without food to facilitate consistent daily intake.

The standard starting dose for adults with hypertension or angina is 5 mg once daily. The dosage should not exceed the maximum adult dose of 10 mg once daily. Any adjustment, or titration, of the dose is typically separated by a minimum of 7 to 14 days to ensure adequate time for assessment of the full effect before proceeding with a change.

Specific dosage rules apply to certain populations. A lower initial dose of 2.5 mg once daily is generally recommended for older adults and individuals with hepatic impairment. For pediatric patients aged 6 to 17 being treated for hypertension, the starting dose is also 2.5 mg once daily, with an absolute maximum of 5 mg once daily. If a scheduled dose is missed, the next dose should be taken at the usual time, and a double dose must not be taken to compensate.

Recent Clinical Evidence

Research evidence / Overview of Studies for Adipin (Amlodipine)


Evidence for Use in Managing High Blood Pressure (Hypertension)

Research exploring Amlodipine's use in managing high blood pressure, or hypertension, has involved large-scale, long-term Randomized Controlled Trials (RCTs). These studies were conducted to evaluate study patterns against a placebo or other treatments for blood pressure. Researchers primarily monitored the measured reduction in blood pressure readings, but also explored the long-term impact on serious cardiovascular events like stroke and myocardial infarction.

Multi-year studies exploring this field reported that groups receiving Amlodipine demonstrated measured patterns of change in blood pressure readings over the observation period. Trials also explored whether the measured patterns in blood pressure readings were associated with differences in the incidence of major cardiovascular events in the observed populations. The research base related to hypertension is substantial, yet data regarding the long-term effects and optimal dosing in children under the age of six remains insufficient.


Evidence for Use in Chronic Stable and Vasospastic Angina

Amlodipine was studied for its role in managing angina, a condition characterized by fluctuating or episodic manifestations of chest discomfort. This research involved Randomized Controlled Trials that primarily focused on outcomes related to physical discomfort and functional limitations. Studies examined patient-reported outcomes describing perceived discomfort and tracked objective measures such as the amount of exercise a patient could perform before symptoms appeared.

Studies conducted during periods of increased symptom activity reported that patients observed changes measured during the study period related to the frequency of anginal episodes. These trials also monitored patient-reported outcomes describing perceived discomfort and findings describe patterns observed in physiological responses during measured exercise tests over the study period. What remains uncertain is the extended monitoring of the effect, as the follow-up durations were limited for many of the symptom-focused trials.


Evidence in Specific Populations and High-Risk Groups

Amlodipine was evaluated in specific populations. High-quality research was observed in adult populations presenting with comorbid conditions, such as diabetes. Similarly, research examined older adults as large subgroups within these major trials. Research has also examined the use of Amlodipine in pediatric patients aged 6 to 17 years who have high blood pressure. Data regarding the use of Amlodipine in pregnancy is not available.

Key Studies & References Amlodipine: MedlinePlus Drug Information (Authoritative Overview)

Frequently Asked Questions (FAQ)

Common questions about Adipin (FAQ)

Q: Is Adipin the same type of medicine as [similar drug name]?

Adipin contains the active substance Amlodipine, which is formally classified as a dihydropyridine calcium channel blocker (CCB). This specific classification of medicine primarily works by causing the relaxation of vascular smooth muscle, a characteristic that is consistent with its use in managing high blood pressure and angina.

Q: Does Adipin cause weight gain or weight loss?

According to the official product information, both weight increase (gain) and weight decrease (loss) are listed as reported adverse reactions in clinical data. However, the regulatory documents indicate that these effects are relatively uncommon, typically occurring in less than one percent of patients observed in the trials.

Q: Does taking Adipin mean I can't drink coffee?

Official regulatory documents and patient information do not list caffeine or coffee as a documented interaction requiring avoidance or dose restriction. It is generally advised for patients to provide their healthcare professional with a complete list of substances for consistent management of the condition.

Q: Do I need to change my diet while taking Adipin?

Official guidance notes that the consumption of grapefruit or grapefruit juice is not recommended while taking this medicine. This is because official information indicates that consuming the fruit may increase the systemic exposure of Amlodipine in certain patients. Otherwise, Amlodipine can be taken with or without food.

Q: What should I know about Adipin and driving?

Due to the potential for common side effects such as dizziness, headache, or fatigue, official guidance advises exercising caution when driving or operating machinery. This caution is relevant during the initial period of treatment or following an adjustment in the dose.

Q: Are there any dietary supplements or vitamins that should not be taken with Adipin?

The regulatory interaction profile includes specific mentions of certain substances, such as the herbal supplement St. John's Wort. It is generally consistent with patient safety practices to inform a healthcare professional about all supplements, vitamins, and herbal products being taken.

Q: Does Adipin interact with alcohol, and what does the regulatory guidance say?

Regulatory guidance classifies the combination of Amlodipine and alcohol as one that should be approached with caution. This is because the two substances may have an additive effect in lowering blood pressure, which may increase the risk of side effects such as dizziness and fainting. Consultation regarding alcohol consumption is generally advised, particularly when beginning the medication.

Q: Why do some forums discuss Adipin needing regular monitoring?

While the medicine requires routine monitoring of blood pressure to confirm efficacy, regulatory guidance advises additional monitoring in specific cases. For instance, close monitoring of liver function is advised for patients with existing hepatic impairment, and blood levels may need to be checked when the medicine is co-administered with certain immunosuppressants.

Q: What does the patient information pamphlet say about stopping Adipin?

According to the official patient information, the medicine is generally intended for chronic, long-term use for managing cardiovascular conditions. Official patient information directs patients to consult a healthcare professional before any change to the medication schedule.

Q: Is it true that Adipin works better if taken at a specific time of day?

The official regulatory label specifies that the dose is taken once daily but does not designate a single 'best' time for superior efficacy. The most important directive is ensuring the dose is taken at a consistent time each day to maintain stable blood levels.

Q: Is Adipin intended for long-term use?

Yes, regulatory documents indicate the drug is studied and authorized for the chronic management of high blood pressure and chronic stable angina. This indicates that the drug is often used for an extended duration to support the management of the condition.

Q: How long does Adipin stay in your system after stopping?

Amlodipine has a long elimination half-life, ranging from 30 to 50 hours. Due to this characteristic, official pharmacokinetic properties indicate the substance takes approximately 6 to 12 days to be almost entirely eliminated from the body.

Q: Can I become dependent on Adipin?

No. Regulatory information sources do not classify Amlodipine as a controlled substance. Official documents and scientific data have established that it has no established risk of drug dependence or addiction.

Q: What are the main things researchers are currently studying about Adipin?

Current research themes continue to examine Amlodipine's use in combination with other agents and its long-term safety profile across various patient populations. This ongoing evaluation is part of the standard process for assessing a widely used medication.

Q: Does Adipin lose effectiveness over time?

Regulatory documents state that Amlodipine demonstrated a sustained reduction in blood pressure throughout clinical trials. There is no official report of tachyphylaxis (a term for loss of effectiveness) over time with continued, chronic use.

Q: Is Adipin available in different forms (e.g., tablet, liquid)?

Yes. Amlodipine is manufactured and approved for use as the common oral tablet. Official product information also confirms that it is available in some markets as an oral solution or suspension.

Q: Why do some users report feeling tired when taking Adipin?

Fatigue and somnolence (sleepiness) are listed as common adverse reactions documented in the official profile. While the precise cause is not always detailed in patient materials, these effects may be related to the medicine's action in the body.

Q: Can Adipin cause an allergic reaction?

Yes. Hypersensitivity to Amlodipine or other related medicines is a status that is listed as a contraindication to use. Rare but serious allergic reactions, such as angioedema (swelling of the face or throat), have been reported in the safety data.

Q: Are there known genetic factors that affect how Adipin works?

Regulatory documents confirm that Amlodipine is metabolized by the CYP3A4 enzyme, which is known to be subject to genetic differences between people. This factor is associated with the variability documented in how the drug is processed.

Q: What is the main patient complaint or question about Adipin?

Based on frequency in clinical trials, the most commonly reported side effect that often leads to patient inquiry is edema, which is characterized by swelling, particularly of the ankles and feet.

How should Adipin be stored and disposed of?

How to Store and Dispose of Adipin?

This section outlines the official, regulatory requirements for the storage, handling, and disposal of Adipin (Amlodipine Oral Tablets).

Official Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with specific instruction to keep from freezing and not store above 30 C [NIH/FDA/EMA].
Protection Keep the tablets in the container it came in, ensuring it is tightly closed. The product must be protected from light and excessive moisture [NIH/USP].
Child Safety Keep out of the sight and reach of children. Always lock safety caps and store the container in a secure, elevated location [MedlinePlus/FDA].

Disposal Instructions

To dispose of unused or expired Adipin, the product must be handled strictly in accordance with local requirements [EMA SmPC]. It is officially mandated that the medication should not be emptied into drains or disposed of with domestic wastewater to prevent environmental contamination [SDS]. Patients are directed to consult their pharmacist or local waste authority for proper procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adipin found in:

A-Z Index: